Boston Scientific opens new R&D center in India

Boston Scientific (NYSE:BSX) has opened its second R&D center in India, located in the western city of Pune.

According to media reports, the new center is 45,000 ft² and will initially employ 170 people, more than doubling the number of R&D employees that Boston Scientific has in India.

The company’s first Indian R&D center opened in Gurgaon in 2014.

“This second R&D Center demonstrates Boston Scientific’s confidence in India’s R&D expertise and provides diverse opportunities for engineers and innovators in the country,” Sanjeev Pandya, director R&D for Boston Scientific India, said in a report by APN News.

 

Read more
  • 0

Medtronic kicks of newly expanded R&D center in India

Medtronic CEO Geoff Martha over videoconferencing helps inaugurate the MEIC with (left to right) Divya Prakash Joshi, senior director and site leader of MEIC; Shri KT Rama Rao, minister for Municipal Administration & Urban Development, Industries & Commerce, and Information Technology for the Indian state of Telangana; Shri Jayesh Ranjan, principal secretary, Industries & Commerce and IT; Shri Shakthi Nagappan, director of Life Sciences & Pharma, Telangana; and Madan Krishnan, VP and managing director of India Medtronic. [Image courtesy of Medtronic]Medtronic (NYSE:MDT) today announced the inauguration of its newly expanded 150,000 ft2 Medtronic Engineering and Innovation Center (MEIC) in Hyderabad, India.

The Fridley, Minn.–based medical device giant is spending $160 million over five years to turn Hyderabad into its largest R&D center outside the U.S. Medtronic expects the number of employees at the facility to reach 1,000.

Given the market s…

Read more
  • 0

India curbs COVID-19 vaccine exports as infections rise

Image courtesy of Unsplash

After the number of COVID-19 infections began to incline steeply, India has decided to retain most of the vaccines produced in the country.

The country has also announced plans to lower the eligibility requirements to all citizens 45 or older starting April 1.

The Serum Institute of India is one of the world’s biggest vaccine manufacturers, and is a central producer of the AstraZeneca vaccine, having exported more than 60 million doses. The status of the country as a vaccine producer has been elevated in recent months as AstraZeneca plans in Europe have grappled with production problems.

India-based Bharat Biotech has also developed a COVID-19 vaccine although demand for the vaccine has been low outside of the country.

Vaccinations in India have lagged behind many other countries  — the country has exported more doses than it has administered. To date in the co…

Read more
  • 0